Investigator Curriculum Vitae

This template may be used by Sponsors of clinical trials as part of the application dossier.

EU CT number:

A separate document should be completed and submitted for each site.

This template has been developed and endorsed by the EU Clinical Trials Expert Group to comply with Regulation (EU) No. 536/2014 Clinical Trials on Medicinal Products for Human Use.

Personal Information

Name:	**Alice Rossi**
Title:	**Sub-Investigator, MD**
Profession:	**Medical Oncologist**
Current position:	**Sub-Investigator, Medical Oncologist**

Professional Registration[i]

Registration number:	07705
Registration body:	Italian Medical Council registration number
Registration expiry date (if applicable):	**N/A**
Registration state/province (if applicable):	**Bergamo**

Education and Qualifications[ii]

Institution name	Qualification	Year
University of Verona, Italy	Postgraduate Specialization in Medical Oncology – University of Verona, Italy (70/70 cum Laude).	November 17, 2023
University of Pavia, Italy	Italian Medical License Exam (IMLE) – University of Pavia, Italy	March 1, 2018

Investigator Curriculum Vitae

University of Pavia, Italy	Master Degree in Medicine and Surgery (Harvey Course) – University of Pavia, Italy (110/110 cum Laude)	July 10, 2017

Current employment

Institution name:	CRC (Centro Ricerche Cliniche), Verona, Italy
Department:	CRC (Centro Ricerche Cliniche)
Institution address:	**Piazzale L.A. Scuro 10, Verona**
Telephone number:	[redacted]
E-mail address:	[redacted]

Professional experience[iii]

Position	Institution name and department	Start year	End year
Sub-Investigator	CRC (Centro Ricerche Cliniche), Verona, Italy	From 17 January 2024	ongoing
PhD Student	"Inflammation, Immunity and Cancer", University of Verona	From 01 October 2024	ongoing
Medical Training	Phase 1 Unit (Director Dr Elena Garralda), Vall d'Hebron Institute Oncology VHIO (Director Dr Josep Tabernero), Barcelona, Spain	July 2023	December 2023

Relevant clinical trial/study experience[iv]

Investigator role	Therapeutic area	Type of trial	Year started	Phase	Ongoing
Sub Investigator	A Phase I, Multicenter, Open-label, First-in Human, Dose	Clinical Study	2024	Phase I	Yes

Investigator Curriculum Vitae

	Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Tumors				
Sub Investigator	A Phase 1 Study of SGN-PDL1V in Advanced Solid Tumors	Clinical Study	2024	**Phase I**	Yes
Sub Investigator	A Phase 1a/1b, Open-Label, Multi-Center, Dose Escalation and Expansion Study of HFB200603 (anti-BTLA antibody) as a Single Agent and in Combination with Tislelizumab (anti-PD-1 antibody) in Adult Patients with Advanced Solid Tumors	Clinical Study	2024	**Phase I**	Yes
Sub Investigator	Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mutant Solid Tumors	Clinical Study	2024	**Phase I**	Yes
Sub Investigator	A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY OF ZANZALINTINIB (XL092) IN COMBINATION WITH PEMBROLIZUMAB VS PEMBROLIZUMAB IN THE FIRST-LINE TREATMENT OF SUBJECTS WITH PD-L1 POSITIVE RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA	Clinical Study	2024	**Phase II**	Yes

Investigator Curriculum Vitae

Training

Research training (including GCP)	Institution name	Year obtained
ALS training - Advanced life support training	Advanced life support	March 15-16, 2024
ICH-GCP training	ICH-GCP training	May 15, 2024
MCCR (EORTC-ESMO-AACR) Workshop on Methods in Clinical Cancer Research	MCCR	June 17-23, 2023

Date completed[v]: 09/10/2024

[i] As per national legislation
[ii] Relevant to be an investigator
[iii] This should cover the preceding 10 years as a maximum
[iv] Idem
[v] The CTR does not require signing individual documents in the clinical trial application – a request for signature could however be subject to national legislation.